bridgebio news - Search News

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.

Bloomberg on MSN · 21h

BridgeBio Soars After Drug Gets Nod in Rare Heart Condition

BridgeBio Pharma Inc. jumped in premarket trading after its drug got US regulators’ nod to treat a deadly form of heart disease, paving the way for head-to-head competition with medications from Pfizer Inc.

GEN · 19h

Bridgebio’s Attruby, to Treat Heart Condition ATTR-CM, Receives FDA Approval

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and hospitalization in ATTR-CM patients.

Reuters · 3d

US FDA approves BridgeBio's drug for rare heart condition

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer's blockbuster Vyndaqel.

MarketWatch · 22h

BridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby

The Palo Alto, California-based biopharmaceutical company said the Food and Drug Administration approved Attruby for adults with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce cardiovascular death and cardiovascular-related hospitalization.

38m

BridgeBio price target raised to $45 from $42 at BofA

BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the FDA approved its stabilizer acoramidis as Attruby for ...

BridgeBio Pharma (NASDAQ:BBIO) Given New $45.00 Price Target at Bank of America

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

FiercePharma1d

Look out, Pfizer: BridgeBio scores 'best-case' FDA nod for Attruby in cardiomyopathy

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

18h

BridgeBio price target raised to $48 from $45 at Scotiabank

Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $48 from $45 and keeps an Outperform rating on the ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...

GlobalData on MSN1d

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...

19h

BridgeBio Pharma’s Hold Rating: Balancing Optimism from Acoramidis Approval with Market and Competitive Concerns

Kostas Biliouris, an analyst from BMO Capital, maintained the Hold rating on BridgeBio Pharma (BBIO – Research Report). The associated price ...

devdiscourse2d

Revolutionary Drug Approvals and Global Health Updates

The latest health news highlights BridgeBio's new heart drug approved by the FDA, novel findings in breast cell research, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Related topics